DNA methylation and cancer diagnosis

International Journal of Molecular Sciences

Volumn 14, Issue 7, 2013, Pages 15029-15058

  Delpu, Yannick ^a,b   Cordelier, Pierre ^a,b   Cho, William C ^c   Torrisani, Jérôme ^a,b  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Biomarkers; Cancer diagnosis; Clinical trials; DNA methylation; DNA methylation inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; DOCETAXEL; ENTINOSTAT; FLAVONOID; FLUCYTOSINE DEOXYRIBOSIDE; GLUTATHIONE TRANSFERASE P1; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDRALAZINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MG 98; MICRORNA; N PHTHALOYLTRYPTOPHAN; PANOBINOSTAT; PEGINTERFERON; PREDNISONE; PROCAINAMIDE; PROTEIN MLH1; SEPTIN 9; SGI 110; TEMOZOLOMIDE; TETRAHYDROURIDINE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE MAGNESIUM; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CAPILLARY ELECTROPHORESIS; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COLON CANCER; CYTODIAGNOSIS; DNA DAMAGE; DNA DETERMINATION; DNA METHYLATION; DRUG EFFICACY; DRUG MECHANISM; EARLY DIAGNOSIS; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENOME IMPRINTING; HEAD AND NECK CANCER; HEART VENTRICLE ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK POPULATION; HISTONE MODIFICATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; MELANOMA; METASTATIC MELANOMA; MOLECULAR DIAGNOSIS; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; PRECANCER; PREDICTIVE VALUE; PROSTATE CANCER; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; UTERINE CERVIX CANCER; VALIDATION PROCESS;

EID: 84880731892     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140715029     Document Type: Review

References (156)

1. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16, 6-21.
2. Gopalakrishnan, S.; van Emburgh, B.O.; Robertson, K.D. DNA methylation in development and human disease. Mutat. Res. 2008, 647, 30-38.
3. Jones, P.A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 2012, 13, 484-492.
4. Chen, T.; Li, E. Structure and function of eukaryotic DNA methyltransferases. Curr. Top. Dev. Biol. 2004, 60, 55-89.
5. Kinney, S.R.M.; Pradhan, S. Regulation of expression and activity of DNA (cytosine-5) methyltransferases in mammalian cells. Prog. Mol. Biol. Transl. Sci. 2011, 101, 311-333.
6. Bachman, K.E.; Rountree, M.R.; Baylin, S.B. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J. Biol. Chem. 2001, 276, 32282-32287.
7. Jeong, S.; Liang, G.; Sharma, S.; Lin, J.C.; Choi, S.H.; Han, H.; Yoo, C.B.; Egger, G.; Yang, A.S.; Jones, P.A. Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol. Cell. Biol. 2009, 29, 5366-5376.
8. Sharma, S.; de Carvalho, D.D.; Jeong, S.; Jones, P.A.; Liang, G. Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet. 2011, 7, e1001286.
9. Okano, M.; Bell, D.W.; Haber, D.A.; Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99, 247-257.
10. Li, E.; Bestor, T.H.; Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69, 915-926.
11. Chedin, F.; Lieber, M.R.; Hsieh, C.L. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proc. Natl. Acad. Sci. USA 2002, 99, 16916-16921.
12. Okano, M.; Xie, S.; Li, E. Dnmt2 is not required for de novo and maintenance methylation of viral DNA in embryonic stem cells. Nucleic Acids Res. 1998, 26, 2536-2540.
13. Goll, M.G.; Kirpekar, F.; Maggert, K.A.; Yoder, J.A.; Hsieh, C.L.; Zhang, X.; Golic, K.G.; Jacobsen, S.E.; Bestor, T.H. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006, 311, 395-398.
14. Tuorto, F.; Liebers, R.; Musch, T.; Schaefer, M.; Hofmann, S.; Kellner, S.; Frye, M.; Helm, M.; Stoecklin, G.; Lyko, F. RNA cytosine methylation by Dnmt2 and NSun2 promotes tRNA stability and protein synthesis. Nat. Struct. Mol. Biol. 2012, 19, 900-905.
15. Jurkowski, T.P.; Shanmugam, R.; Helm, M.; Jeltsch, A. Mapping the tRNA binding site on the surface of human DNMT2 methyltransferase. Biochemistry 2012, 51, 4438-4444.
16. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128, 683-692.
17. Berdasco, M.; Esteller, M. Aberrant epigenetic landscape in cancer: How cellular identity goes awry. Dev. Cell 2010, 19, 698-711.
18. Wild, L.; Flanagan, J.M. Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim. Biophys. Acta 2010, 1806, 50-57.
19. Pastor, W.A.; Aravind, L.; Rao, A. TETonic shift: Biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 2013, 14, 341-356.
20. Hashimoto, H.; Liu, Y.; Upadhyay, A.K.; Chang, Y.; Howerton, S.B.; Vertino, P.M.; Zhang, X.; Cheng, X. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 2012, 40, 4841-4849.
21. Valinluck, V.; Sowers, L.C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007, 67, 946-950.
22. He, Y.-F.; Li, B.-Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L.; et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333, 1303-1307.
23. Song, C.-X.; Clark, T.A.; Lu, X.Y.; Kislyuk, A.; Dai, Q.; Turner, S.W.; He, C.; Korlach, J. Sensitive and specific single-molecule sequencing of 5-hydroxymethylcytosine. Nat. Methods 2012, 9, 75-77.
24. Sun, M.; Song, C.X.; Huang, H.; Frankenberger, C.A.; Sankarasharma, D.; Gomes, S.; Chen, P.; Chen, J.; Chada, K.K.; He, C.; et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc. Natl. Acad. Sci. USA 2013, 110, 9920-9925.
25. Hsu, C.-H.; Peng, K.L.; Kang, M.L.; Chen, Y.R.; Yang, Y.C.; Tsai, C.H.; Chu, C.S.; Jeng, Y.M.; Chen, Y.T.; Lin, F.M.; et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012, 2, 568-579.
26. Liu, C.; Liu, L.; Chen, X.; Shen, J.; Shan, J.; Xu, Y.; Yang, Z.; Wu, L.; Xia, F.; Bie, P.; et al. Decrease of 5-Hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One 2013, 8, e62828.
27. Maul, R.W.; Gearhart, P.J. AID and somatic hypermutation. Adv. Immunol. 2010, 105, 159-191.
28. Bhutani, N.; Brady, J.J.; Damian, M.; Sacco, A.; Corbel, S.Y.; Blau, H.M. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010, 463, 1042-1047.
29. Métivier, R.; Gallais, R.; Tiffoche, C.; Le Péron, C.; Jurkowska, R.Z.; Carmouche, R.P.; Ibberson, D.; Barath, P.; Demay, F.; Reid, G.; et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008, 452, 45-50.
30. Kalari, S.; Pfeifer, G.P. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv. Genet. 2010, 70, 277-308.
31. Peng, D.F.; Kanai, Y.; Sawada, M.; Ushijima, S.; Hiraoka, N.; Kosuge, T.; Hirohashi, S. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci. 2005, 96, 403-408.
32. Belinsky, S.A.; Nikula, K.J.; Baylin, S.B.; Issa, J.P. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc. Natl. Acad. Sci. USA 1996, 93, 4045-4050.
33. Lopatina, N.G.; Vanyushin, B.F.; Cronin, G.M.; Poirier, L.A. Elevated expression and altered pattern of activity of DNA methyltransferase in liver tumors of rats fed methyl-deficient diets. Carcinogenesis 1998, 19, 1777-1781.
34. Sato, N.; Fukushima, N.; Hruban, R.H.; Goggins, M. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod. Pathol. 2007, 21, 238-244.
35. Hanoun, N.; Delpu, Y.; Suriawinata, A.A.; Bournet, B.; Bureau, C.; Selves, J.; Tsongalis, G.J.; Dufresne, M.; Buscail, L.; Cordelier, P.; et al. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin. Chem. 2010, 56, 1107-1118.
36. House, M.G.; Guo, M.; Iacobuzio-Donahue, C.; Herman, J.G. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003, 24, 193-198.
37. Lee, J.-H.; Park, S.-.J.; Abraham, S.C.; Seo, J.-.S.; Nam, J.-.H.; Choi, C.; Juhng, S.-.W.; Rashid, A.; Hamilton, S.R.; Wu, T.-.T. Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 2004, 23, 4646-4654.
38. Brooks, J.D.; Weinstein, M.; Lin, X.; Sun, Y.; Pin, S.S.; Bova, G.S.; Epstein, J.I.; Isaacs, W.B.; Nelson, W.G. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomark. Prev. 1998, 7, 531-536.
39. Robertson, K.D.; Uzvolgyi, E.; Liang, G.; Talmadge, C.; Sumegi, J.; Gonzales, F.A.; Jones, P.A. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999, 27, 2291-2298.
40. El-Deiry, W.S.; Nelkin, B.D.; Celano, P.; Yen, R.-W.C.; Falco, J.P.; Hamilton, S.R.; Baylin, S.B. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc. Natl. Acad. Sci. USA 1991, 88, 3470-3474.
41. Girault, I.; Tozlu, S.; Lidereau, R.; Bièche, I. Expression Analysis of DNA Methyltransferases 1, 3A, and 3B in Sporadic Breast Carcinomas. Clin. Cancer Res. 2003, 9, 4415-4422.
42. Mizuno, S.; Chijiwa, T.; Okamura, T.; Akashi, K.; Fukumaki, Y.; Niho, Y.; Sasaki, H. Expression of DNA methyltransferases DNMT1,3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001, 97, 1172-1179.
43. Robertson, K.D. DNA methylation, methyltransferases, and cancer. Oncogene 2001, 20, 3139-3155.
44. Gaidzik, V.I.; Paschka, P.; Späth, D.; Habdank, M.; Köhne, C.-H.; Germing, U.; von Lilienfeld-Toal, M.; Held, G.; Horst, H.-A.; Haase, D.; et al. TET2 Mutations in Acute Myeloid Leukemia (AML): Results from a comprehensive genetic and clinical analysis of the AML study group. J. Clin. Oncol. 2012, 30, 1350-1357.
45. Simó-Riudalbas, L.; Melo, S.A.; Esteller, M. DNMT3B gene amplification predicts resistance to DNA demethylating drugs. Genes Chromosomes Cancer 2011, 50, 527-534.
46. Lopez de Silanes, I.; Gorospe, M.; Taniguchi, H.; Abdelmohsen, K.; Srikantan, S.; Alaminos, M.; Berdasco, M.; Urdinguio, R.G.; Fraga, M.F.; Jacinto, F.V.; et al. The RNA-binding protein HuR regulates DNA methylation through stabilization of DNMT3b mRNA. Nucleic Acids Res. 2009, 37, 2658-2671.
47. Ley, T.J.; Ding, L.; Walter, M.J.; McLellan, M.D.; Lamprecht, T.; Larson, D.E.; Kandoth, C.; Payton, J.E.; Baty, J.; Welch, J.; et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 2010, 363, 2424-2433.
48. Singer, J.; Stellwagen, R.H.; Roberts-Ems, J.; Riggs, A.D. 5-Methylcytosine content of rat hepatoma DNA substituted with bromodeoxyuridine. J. Biol. Chem. 1977, 252, 5509-5513.
49. Fraga, M.F.; Rodríguez, R.; Cañal, M.J. Rapid quantification of DNA methylation by high performance capillary electrophoresis. Electrophoresis 2000, 21, 2990-2994.
50. Ramsahoye, B.H. Nearest-neighbor analysis. Methods Mol. Biol. 2002, 200, 9-15.
51. Guerrero-Preston, R.; Santella, R.M.; Blanco, A.; Desai, M.; Berdasco, M.; Fraga, M. Global DNA hypomethylation in liver cancer cases and controls: A phase I preclinical biomarker development study. Epigenetics 2007, 2, 223-226.
52. Costello, J.F.; Smiraglia, D.J.; Plass, C. Restriction landmark genome scanning. Methods 2002, 27, 144-149.
53. Frigola, J.; Ribas, M.; Risques, R.-A.; Peinado, M.A. Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res. 2002, 30, e28.
54. Liang, G.; Chan, M.F.; Tomigahara, Y.; Tsai, Y.C.; Gonzales, F.A.; Li, E.; Laird, P.W.; Jones, P.A. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol. Cell. Biol. 2002, 22, 480-491.
55. Frommer, M.; McDonald, L.E.; Millar, D.S.; Collis, C.M.; Watt, F.; Grigg, G.W.; Molloy, P.L.; Paul, C.L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 1992, 89, 1827-1831.
56. Herman, J.G.; Graff, J.R.; Myöhänen, S.; Nelkin, B.D.; Baylin, S.B. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996, 93, 9821-9826.
57. Yamamoto, N.; Nakayama, T.; Kajita, M.; Miyake, T.; Iwamoto, T.; Kim, S.J.; Sakai, A.; Ishihara, H.; Tamaki, Y.; Noguchi, S. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res. Treat. 2012, 132, 165-173.
58. Xiong, Z.; Laird, P.W. COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997, 25, 2532-2534.
59. Eads, C.A.; Danenberg, K.D.; Kawakami, K.; Saltz, L.B.; Blake, C.; Shibata, D.; Danenberg, P.V.; Laird, P.W. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28, E32.
60. Tost, J.; Gut, I.G. DNA methylation analysis by pyrosequencing. Nat. Protoc. 2007, 2, 2265-2275.
61. Zhang, X.; Yazaki, J.; Sundaresan, A.; Cokus, S.; Chan, S.W.-.L.; Chen, H.; Henderson, I.R.; Shinn, P.; Pellegrini, M.; Jacobsen, S.E.; et al. Genome-wide high-resolution mapping and functional analysis of DNA methylation in arabidopsis. Cell 2006, 126, 1189-1201.
62. Taylor, K.H.; Kramer, R.S.; Davis, J.W.; Guo, J.; Duff, D.J.; Xu, D.; Caldwell, C.W.; Shi, H. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res. 2007, 67, 8511-8518.
63. Kulis, M.; Heath, S.; Bibikova, M.; Queirós, A.C.; Navarro, A.; Clot, G.; Martínez-Trillos, A.; Castellano, G.; Brun-Heath, I.; Pinyol, M.; et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 2012, 44, 1236-1242.
64. Bibikova, M.; Lin, Z.; Zhou, L.; Chudin, E.; Garcia, E.W.; Wu, B.; Doucet, D.; Thomas, N.J.; Wang, Y.; Vollmer, E.; et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 2006, 16, 383-393.
65. Dedeurwaerder, S.; Desmedt, C.; Calonne, E.; Singhal, S.K.; Haibe-Kains, B.; Defrance, M.; Michiels, S.; Volkmar, M.; Deplus, R.; Luciani, J.; et al. DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol. Med. 2011, 3, 726-741.
66. Liloglou, T.; Field, J.K. Detection of DNA methylation changes in body fluids. Adv. Genet. 2010, 71, 177-207.
67. Carvalho, A.L.; Henrique, R.; Jeronimo, C.; Nayak, C.S.; Reddy, A.N.; Hoque, M.O.; Chang, S.; Brait, M.; Jiang, W.-.W.; Kim, M.M.; et al. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin. Cancer Res. 2011, 17, 4782-4789.
68. Anglim, P.P.; Alonzo, T.A.; Laird-Offringa, I.A. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: An update. Mol. Cancer 2008, 7, 81.
69. Yan, L.; McFaul, C.; Howes, N.; Leslie, J.; Lancaster, G.; Wong, T.; Threadgold, J.; Evans, J.; Gilmore, I.; Smart, H.; et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005, 128, 2124-2130.
70. Matsubayashi, H.; Canto, M.; Sato, N.; Klein, A.; Abe, T.; Yamashita, K.; Yeo, C.J.; Kalloo, A.; Hruban, R.; Goggins, M. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. 2006, 66, 1208-1217.
71. Wagner, P.D.; Verma, M.; Srivastava, S. Challenges for biomarkers in cancer detection. Ann. N. Y. Acad. Sci. 2004, 1022, 9-16.
72. Rocco, J.W.; Sidransky, D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp. Cell Res. 2001, 264, 42-55.
73. Zou, H.-Z.; Yu, B.-M.; Wang, Z.-W.; Sun, J.-Y.; Cang, H.; Gao, F.; Li, D.H.; Zhao, R.; Feng, G.-G.; Yi, J. Detection of Aberrant p16 Methylation in the Serum of Colorectal Cancer Patients. Clin. Cancer Res. 2002, 8, 188-191.
74. Wong, I.H.N.; Lo, Y.M.D.; Zhang, J.; Liew, C.-T.; Ng, M.H.L.; Wong, N.; Lai, P.B.S.; Lau, W.Y.; Hjelm, N.M.; Johnson, P.J. Detection of Aberrant p16 Methylation in the Plasma and Serum of Liver Cancer Patients. Cancer Res. 1999, 59, 71-73.
75. Belinsky, S.A.; Nikula, K.J.; Palmisano, W.A.; Michels, R.; Saccomanno, G.; Gabrielson, E.; Baylin, S.B.; Herman JG. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA 1998, 95, 11891-11896.
76. Kaina, B.; Margison, G.P.; Christmann, M.; Targeting, O. 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell. Mol. Life Sci. 2010, 67, 3663-3681.
77. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343, 1350-1354.
78. Shen, L.; Kondo, Y.; Rosner, G.L.; Xiao, L.; Hernandez, N.S.; Vilaythong, J.; Houlihan, P.S.; Krouse, R.S.; Prasad, A.R; Einspahr, J.G.; et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J. Natl. Cancer Inst. 2005, 97, 1330-1338.
79. Townsend, D.M.; Tew, K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22, 7369-7375.
80. Nakamichi, I.; Tomita, Y.; Zhang, B.; Sugiyama, H.; Kanakura, Y.; Fukuhara, S.; Hino, M.; Kanamaru, A.; Ogawa, H.; Aozasa, K. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann. Hematol. 2007, 86, 557-564.
81. Miyake, T.; Nakayama, T.; Naoi, Y.; Yamamoto, N.; Otani, Y.; Kim, S.J.; Shimazu, K; Shimomura, A.; Maruyama, N.; Tamaki, Y.; et al. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci. 2012, 103, 913-920.
82. Zhang, Y.; Qu, X.; Jing, W.; Hu, X.; Yang, X.; Hou, K.; Teng, Y.; Zhang, J.; Liu, Y. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: Regulation by promoter methylation and extracellular regulated kinase signaling. Anticancer Drugs 2009, 20, 208-214.
83. Harden, S.V.; Guo, Z.; Epstein, J.I.; Sidransky, D. Quantitative Gstp1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J. Urol. 2003, 169, 1138-1142.
84. Saxena, A.; Dhillon, V.S.; Shahid, M.; Khalil, H.S.; Rani, M.; Prasad, D.A.S.T.; Hedau, S.; Hussain, A.; Naqvi, R.A.; Deo, S.V.S.; et al. GSTP1 methylation and polymorphism increase the risk of breast cancer and the effects of diet and lifestyle in breast cancer patients. Exp. Ther. Med. 2012, 4, 1097-1103.
85. Hashad, D.I.; Hashad, M.M.E.I.; Talaat, I.M.; Ibrahim, M.A. Role of glutathione-S-transferase P1 hypermethylation in molecular detection of prostate cancer. Genet Test Mol. Biomark. 2011, 15, 667-670.
86. Fukui, K. DNA Mismatch Repair in Eukaryotes and Bacteria. J. Nucleic Acids 2010, 2010, 1-16.
87. Kantelinen, J.; Kansikas, M.; Korhonen, M.K.; Ollila, S.; Heinimann, K.; Kariola, R.; Nyström, M. MutSbeta exceeds MutSalpha in dinucleotide loop repair. Br. J. Cancer 2010, 102, 1068-1073.
88. Menigatti, M.; Di Gregorio, C.; Borghi, F.; Sala, E.; Scarselli, A.; Pedroni, M.; Foroni, M.; Benatti, P.; Roncucci, L.; Ponz de Leon, M.;et al. Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes Cancer 2001, 31, 357-361.
89. Bischoff, J.; Ignatov, A.; Semczuk, A.; Schwarzenau, C.; Ignatov, T.; Krebs, T.; Küster, D.; Przadka-Rabaniuk, D.; Roessner, A.; Costa, S.D.; et al. hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin. Exp. Metastasis 2012, 29, 889-900.
90. Ozdemir, F.; Altinisik, J.; Karateke, A.; Coksuer, H.; Buyru, N. Methylation of tumor suppressor genes in ovarian cancer. Exp. Ther. Med. 2012, 4, 1092-1096.
91. Esteller, M.; Corn, P.G.; Baylin, S.B.; Herman, J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61, 3225-3229.
92. Venkitaraman, A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108, 171-182.
93. Esteller, M.; Silva, J.M.; Dominguez, G.; Bonilla. F.; Matias-Guiu, X.; Lerma, E.; Bussaglia, E.; Prat, J.; Harkes, I.C.; Repasky, E.A.; et al. Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors. J. Natl. Cancer Inst. 2000, 92, 564-569.
94. Dobrovic, A.; Simpfendorfer, D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997, 57, 3347-3350.
95. Lofton-Day, C.; Model, F.; DeVos, T.; Tetzner, R.; Distler, J.; Schuster, M.; Song, X.; Lesche, R.; Liebenberg, V.; Ebert, M.; et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 2008, 54, 414-423.
96. Bennett, K.L.; Karpenko, M.; Lin, M.; Claus, R.; Arab, K.; Dyckhoff, G.; Plinkert, P.; Herpel, E.; Smiraglia, D.; Plass, C. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res. 2008, 68, 4494-4499.
97. Connolly, D.; Yang, Z.; Castaldi, M.; Simmons, N.; Oktay, M.H.; Coniglio, S.; Fazzarim M.J.; Verdier-Pinard, P.; Montagna, C. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res. 2011, 13, R76.
98. Grützmann, R.; Molnar, B.; Pilarsky, C.; Habermann, J.K.; Schlag, P.M.; Saeger, H.D.; Miehlke, S.; Stolz, T.; Model, F.; Roblick, U.J.; et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008, 3, e3759.
99. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834-838.
100. Iorio, M.V.; Visone, R.; Leva, G.D.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C.-G.; Alder, H.; et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67, 8699-8707.
101. Weber, B.; Stresemann, C.; Brueckner, B.; Lyko, F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007, 6, 1001-1005.
102. Saito, Y.; Liang, G.; Egger, G.; Friedman, J.M.; Chuang, J.C.; Coetzee, G.A.; Jones, P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9, 435-443.
103. Lehmann, U.; Hasemeier, B.; Christgen, M.; Müller, M.; Römermann, D.; Länger, F.; Kreipe, H. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J. Pathol. 2008, 214, 17-24.
104. Wong, K.Y.; Huang, X.; Chim, C.S. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis 2012, 33, 1629-1638.
105. Cordelier, P.; Torrisani, J. MicroRNAs in Pancreatic Cancer: Potential Interests as Biomarkers and Therapeutic Tools. In MicroRNAs in Cancer Translational Research; Cho, W.C.S., Ed.; Springer: Dordrecht, The Netherlands, 2011; pp. 287-307.
106. Sato, N.; Fukushima, N.; Matsubayashi, H.; Goggins, M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2004, 23, 1531-1538.
107. Wang, Q.; Williamson, M.; Bott, S.; Brookman-Amissah, N.; Freeman, A.; Nariculam, J.; Hubank, M.J.F.; Ahmed, A.; Masters, J.R. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007, 26, 6560-6565.
108. Ogino, S.; Nosho, K.; Kirkner, G.J.; Kawasaki, T.; Chan, A.T.; Schernhammer, E.S.; Giovannucci, E.L.; Fuchs, C.S. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl. Cancer Inst. 2008, 100, 1734-1738.
109. Koerner, M.V.; Barlow, D.P. Genomic imprinting-an epigenetic gene-regulatory model. Curr. Opin. Genet. Develop. 2010, 20, 164-170.
110. Jelinic, P.; Shaw, P. Loss of imprinting and cancer. J. Pathol. 2007, 211, 261-268.
111. Mulero-Navarro, S.; Esteller, M. Epigenetic biomarkers for human cancer: The time is now. Crit. Rev. Oncol. Hematol. 2008, 68, 1-11.
112. McCluskey, L.L.; Chen, C.; Delgadillo, E.; Felix, J.C.; Muderspach, L.I.; Dubeau, L. Differences inp16Gene methylation and expression in benign and malignant ovarian tumors. Gynecol. Oncol. 1999, 72, 87-92.
113. Fujiwara, K.; Fujimoto, N.; Tabata, M.; Nishii, K.; Matsuo, K.; Hotta, K.; Kozuki, T.; Aoe, M.; Kiura, K.; Ueoka, H.; et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 2005, 11, 1219-1225.
114. Müller, H.M.; Oberwalder, M.; Fiegl, H.; Morandell, M.; Goebel, G.; Zitt, M.; Mühlthaler, M.; Öfner, D.; Margreiter, R.; Widschwendter, M. Methylation changes in faecal DNA: A marker for colorectal cancer screening? Lancet 2004, 363, 1283-1285.
115. Stumpel, D.J.P.M.; Schneider, P.; van Roon, E.H.J.; Boer, J.M.; de Lorenzo, P.; Valsecchi, M.G.; de Menezes, R.X.; Pieters, R.; Stam, R.W. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009, 114, 5490-5498.
116. Figueroa, M.E.; Lugthart, S.; Li, Y.; Erpelinck-Verschueren, C.; Deng, X.; Christos, P.J.; Schifano, E.; Booth, J.; van Putten, W.; Skrabanek, L.; et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17, 13-27.
117. Noushmehr, H.; Weisenberger, D.J.; Diefes, K.; Phillips, H.S.; Pujara, K.; Berman, B.P.; Pan, F.; Pelloski, C.E.; Sulman, E.P.; Bhat, K.P. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17, 510-522.
118. Uhlmann, K.; Rohde, K.; Zeller, C.; Szymas, J.; Vogel, S.; Marczinek, K.; Thiel, G.; Nürnberg, P.; Laird, P.W. Distinct methylation profiles of glioma subtypes. Int. J. Cancer 2003, 106, 52-59.
119. Hinoue, T.; Weisenberger, D.J.; Lange, C.P.E.; Shen, H.; Byun, H.-M.; Van Den Berg, D.; Malik, S.; Pan, F.; Noushmehr, H.; van Dijk, C.M.; et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012, 22, 271-282.
120. Ransohoff, D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 2004, 4, 309-314.
121. Mikeska, T.; Bock, C.; Do, H.; Dobrovic, A. DNA methylation biomarkers in cancer: Progress towards clinical implementation. Expert Rev. Mol. Diagn. 2012, 12, 473-487.
122. Gros, C.; Fahy, J.; Halby, L.; Dufau, I.; Erdmann, A.; Gregoire, J.-M.; Ausseil, F.; Vispé, S.; Arimondo, P.B. DNA methylation inhibitors in cancer: Recent and future approaches. Biochimie 2012, 94, 2280-2296.
123. Santi, D.V.; Norment, A.; Garrett, C.E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl. Acad. Sci. USA 1984, 81, 6993-6997.
124. Cheng, J.C.; Yoo, C.B.; Weisenberger, D.J.; Chuang, J.; Wozniak, C.; Liang, G.; Marquez, V.E.; Greer, S.; Orntoft, T.F.; Thykjaer, T.; et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004, 6, 151-158.
125. Lübbert, M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr. Top. Microbiol. Immunol. 2000, 249, 135-164.
126. Robak, T. New nucleoside analogs for patients with hematological malignancies. Expert Opin. Investig. Drugs 2011, 20, 343-359.
127. Tsai, H.-C.; Li, H.; Van Neste, L.; Cai, Y.; Robert, C.; Rassool, F.V.; Shin, J.J.; Harbom, K.M.; Beaty, R.; Pappou, E.; et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21, 430-446.
128. Juergens, R.A.; Wrangle, J.; Vendetti, F.P.; Murphy, S.C.; Zhao, M.; Coleman, B.; Sebree, R.; Rodgers, K.; Hooker, C.M.; Franco, N.; et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1, 598-607.
129. Filì, C.; Malagola, M.; Follo, M.Y.; Finelli, C.; Iacobucci, I.; Martinelli, G.; Cattina, F.; Clissa, C.; Candoni, A.; Fanin, R.; et al. Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin. Cancer Res. 2013, 19, 3297-3308.
130. Passweg, J.R.; Pabst, T.; Blum, S.; Bargetzi, M.; Li, Q.; Heim, D.; Stussi, G.; Gregor, M.; Leoncini, L.; Meyer-Monard, S.; et al. Azacytidine for acute myeloid leukemia in elderly or frail patients: A phase II trial (SAKK 30/07). Leuk. Lymphoma 2013, doi:10.3109/10428194.2013.790540.
131. Gore, S.D.; Fenaux, P.; Santini, V.; Bennett, J.M.; Silverman, L.R.; Seymour, J.F.; Hellstrom-Lindberg, E.; Swern, A.S.; Beach, C.L.; List, A.F.; et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013, doi:10.3324/haematol.2012.074831.
132. Bryan, J.; Kantarjian, H.; Garcia-Manero, G.; Jabbour, E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin. Drug Metab. Toxicol. 2011, 7, 661-672.
133. Matoušová, M.; Votruba, I.; Otmar, M.; Tloušťová, E.; Günterová, J.; Mertlíková-Kaiserová, H. 2'-deoxy-5,6-dihydro-5-azacytidine-a less toxic alternative of 2'-deoxy-5-azacytidine: A comparative study of hypomethylating potential. Epigenetics 2011, 6, 769-776.
134. Chuang, J.C.; Warner, S.L.; Vollmer, D.; Vankayalapati, H.; Redkar, S.; Bearss, D.J.; Qiu, X.; Yoo, C.B.; Jones, P.A. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol. Cancer Ther. 2010, 9, 1443-1450.
135. Schroeder, G.K.; Zhou, L.; Snider, M.J.; Chen, X.; Wolfenden, R. Flight of a cytidine deaminase complex with an imperfect transition state analogue inhibitor: Mass spectrometric evidence for the presence of a trapped water molecule. Biochemistry 2012, 51, 6476-6486.
136. Zhou, L.; Cheng, X.; Connolly, B.A.; Dickman, M.J.; Hurd, P.J.; Hornby, D.P. Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol. 2002, 321, 591-599.
137. Scott, S.A.; Lakshimikuttysamma, A.; Sheridan, D.P.; Sanche, S.E.; Geyer, C.R.; DeCoteau, J.F. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp. Hematol. 2007, 35, 263-273.
138. Yoo, C.B.; Chuang, J.C.; Byun, H.-M.; Egger, G.; Yang, A.S.; Dubeau, L.; Long, T.; Laird, P.W.; Marquez, V.E.; Jones, P.A. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev. Res. 2008, 1, 233-240.
139. Flotho, C.; Claus, R.; Batz, C.; Schneider, M.; Sandrock, I.; Ihde, S.; Plass, C.; Niemeyer, C.M.; Lübbert, M. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009, 23, 1019-1028.
140. Chik, F.; Szyf, M. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 2011, 32, 224-232.
141. Fahy, J.; Jeltsch, A.; Arimondo, P.B. DNA methyltransferase inhibitors in cancer: A chemical and therapeutic patent overview and selected clinical studies. Expert Opin. Ther. Pat. 2012, 22, 1427-1442.
142. Cornacchia, E.; Golbus, J.; Maybaum, J.; Strahler, J.; Hanash, S.; Richardson, B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 1988, 140, 2197-2200.
143. Segura-Pacheco, B.; Trejo-Becerril, C.; Perez-Cardenas, E.; Taja-Chayeb, L.; Mariscal, I.; Chavez, A.; Acuña, C.; Salazar, A.M.; Lizano, M.; Dueñas-Gonzalez, A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res. 2003, 9, 1596-1603.
144. Zambrano, P.; Segura-Pacheco, B.; Perez-Cardenas, E.; Cetina, L.; Revilla-Vazquez, A.; Taja-Chayeb, L.; Chavez-Blanco, A.; Angeles, E.; Cabrera, G.; Sandoval, K.; et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005, 5, 44.
145. Chuang, J.C.; Yoo, C.B.; Kwan, J.M.; Li, T.W.H.; Liang, G.; Yang, A.S.; Jones, P.A. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol. Cancer Ther. 2005, 4, 1515-1520.
146. Fenster, P.E.; Comess, K.A.; Marsh, R.; Katzenberg, C.; Hager, W.D. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am. Heart J. 1983, 106, 501-504.
147. Villar-Garea, A.; Fraga, M.F.; Espada, J.; Esteller, M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003, 63, 4984-4989.
148. Lee, B.H.; Yegnasubramanian, S.; Lin, X.; Nelson, W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J. Biol. Chem. 2005, 280, 40749-40756.
149. Stresemann, C.; Brueckner, B.; Musch, T.; Stopper, H.; Lyko, F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006, 66, 2794-2800.
150. Halby, L.; Champion, C.; Sénamaud-Beaufort, C.; Ajjan, S.; Drujon, T.; Rajavelu, A.; Ceccaldi, A.; Jurkowska, R.; Lequin, O.; Nelson, W.G.; et al. Rapid synthesis of new DNMT inhibitors derivatives of procainamide. Chembiochem 2012, 13, 157-165.
151. Lin, Y.-S.; Shaw, A.Y.; Wang, S.-G.; Hsu, C.-C.; Teng, I.-W.; Tseng, M.-J.; Huang, T.H.; Chen, C.-S.; Leu, Y.-W.; Hsiao, S.-H. Identification of novel DNA methylation inhibitors via a two-component reporter gene system. J. Biomed. Sci. 2011, 18, 3.
152. Fang, M.Z.; Chen, D.; Sun, Y.; Jin, Z.; Christman, J.K.; Yang, C.S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 2005, 11, 7033-7041.
153. Lee, W.J.; Shim, J.-Y.; Zhu, B.T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 2005, 68, 1018-1030.
154. Wang, Y.; Li, Y.; Liu, X.; Cho, W.C. Genetic and epigenetic studies for determining molecular targets of natural product anticancer agents. Curr. Cancer Drug Targets 2013, 13, 506-518.
155. Plummer, R.; Vidal, L.; Griffin, M.; Lesley, M.; de Bono, J.; Coulthard, S.; Sludden, J.; Siu, L.L.; Chen, E.X.; Oza, A.M.; et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15, 3177-3183.
156. Klisovic, R.B.; Stock, W.; Cataland, S.; Klisovic, M.I.; Liu, S.; Blum, W.; Green, M.; Odenike, O.; Godley, L.; Burgt, J.V. et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin. Cancer Res. 2008, 14, 2444-2449.